Roche has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the ACCU-CHEK Inform II system, a next-generation blood glucose monitor for hospital point-of-care testing.
ACCU-CHEK Inform II, New Hospital Point-Of-Care System for Blood Glucose Testing Receives FDA Approval
The ACCU-CHEK Inform II system is a wireless hospital blood glucose device that utilizes new patented technology to deliver improved accuracy. The system enables automatic real-time wireless transfer of patient data between hospital medical staff and the laboratory.
“Accuracy and patient safety are the foremost concerns for blood glucose testing in hospitals and other point-of-care settings,” said Roland Diggelmann, chief operating officer at Roche Diagnostics. “ACCU-CHEK systems have been proven in hospitals around the world and this next-generation wireless system sets a new standard by offering U.S. healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care.”
The ACCU-CHEK Inform II meter and test strip enables healthcare professionals to obtain test results in just five seconds using a small 0.6 microliter capillary blood sample. Additional features include unique patient identifiers to improve the accuracy of patient identification and a durable design to meet stringent cleaning and disinfecting guidelines. The test results are not affected by interference from maltose, xylose or oxygen. These results transfer quickly through the wireless network to give health care providers actionable information.
The ACCU-CHEK system is expected to be available in the U.S. in October 2012.
Company websiteRoche Applied Science - a member of the Roche Group